GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Accounts Receivable

GILD (Gilead Sciences) Accounts Receivable : $4,420 Mil (As of Dec. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Gilead Sciences's accounts receivables for the quarter that ended in Dec. 2024 was $4,420 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Gilead Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 53.29.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Gilead Sciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-19.20.


Gilead Sciences Accounts Receivable Historical Data

The historical data trend for Gilead Sciences's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Accounts Receivable Chart

Gilead Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,892.00 4,493.00 4,777.00 4,660.00 4,420.00

Gilead Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,660.00 4,669.00 4,663.00 4,587.00 4,420.00

Gilead Sciences Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Gilead Sciences Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Gilead Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=4420/7569*91
=53.29

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Gilead Sciences's accounts receivable are only considered to be worth 75% of book value:

Gilead Sciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(11568+0.75 * 4420+0.5 * 1710-39749
-0--84)/1246.266
=-19.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Gilead Sciences Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711